Pricing Log in Create free account
Friday 6 November 2026 Export ASND’s income statement to Excel — free account

Ascendis Pharma A/S

ASND Healthcare Biotechnology

Ascendis Pharma A/S’s revenue for fiscal 2025 (year ended December 2025) was $814.8 million, up 107.1% from fiscal 2024.

Revenue
+119.9%
EPS
+612.3%
Free cash flow
+2,335.9%
Total debt
−41.8%

Quarter to June 2026, against a year earlier

253.63 0.18 +0.07%
Market cap
$16.6B
P/E
18.3×
Fwd P/E
15.4×
Dividend yield
—
F-score
5/9
Altman Z
2.02
Beneish M
−2.51
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Bought, $m 0.78
Sold, $m 5.45
Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — — — — 3 1 — 1 — — —
Sell — — — — — 1 — — — 1 — —
Insider Ownership 0.00%

Capital & Financial Ratios $m

Size
Market Cap 16,640.00
Revenue ttm 1,212.10
Net income ttm 865.91
Free cash flow ttm 387.49
Net debt Q (421.11)
Valuation
P/E 18.30
Forward P/E 15.40
Price / sales 13.47 (above 10: high)
Forward P/S Powerpack
Price / FCF 42.14
Price / book 9.78 (above 6: high)
Financial health
Current ratio Q 2.99 (at or above 1.5: strong)
Debt / equity Q 0.31 (at or below 0.5: strong)
Interest coverage Q 15.56
Growth
Revenue growth Q +119.88% (above 0%: growing)
Operating income growth Q +526.44% (above 0%: growing)
EPS, this year +483.29% (at or above 15%: strong)
EPS, next year A −37.31% (below 0%: weak)
Revenue, next year A +68.64% (at or above 10%: strong)
EPS, past 5 yrs —
EPS, next 5 yrs A +38.10% (at or above 15%: strong)

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 13.1×, against a ten-year median of 180×; over the ten years it ranged from 11.7× in 2026 to 5,964× in 2018.
P/S against its own 10 years 2.38%
10-year low 10-year high
P/B against its own 10 years 74.17%
10-year low 10-year high
EV/Sales against its own 10 years 2.16%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 432 605 697 944
Receivables 60 192 178 261
Inventory 226 320 341 361
Other — — — —
761 1,148 1,255 1,617
2023 2024 2025 Q'26
Payables 102 104 103 121
ST’ Debt 12 532 550 76
Other 81 345 550 329
214 982 1,210 541

Compound Annual Growth %

10y 5y 3y
Sales 56.90% 152.47% 147.23%
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value 0.00% 0.00% 0.00%

Earnings Trends EPS, adjusted, against the consensus

Jun 2026 Estimate 0.78 Actual 3.29

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Sep 2025 −0.41 −1.17 Miss by 0.76
Dec 2025 −0.06 −0.64 Miss by 0.58
Mar 2026 0.21 0.32 Beat by 0.11
Jun 2026 0.78 3.29 Beat by 2.51
Sep 2026 1.13 — Reports 11 November 2026

EPS $

Mar Jun Sep Dec Year
’26 11.41 3.29 — — —
’25 (1.66) (0.69) (1.17) (0.64) (4.25)
’24 (2.48) (2.05) (1.89) (0.68) (7.07)
’23 (2.12) (2.35) (3.12) (1.66) (9.24)
’22 (2.48) (1.54) (3.05) (3.78) (10.96)
’21 (1.41) (3.01) (1.73) (2.14) (8.28)
’20 (1.46) (2.17) (2.70) (3.15) (9.46)
Fiscal quarters ending in the months shown.

Revenue $m

Mar Jun Sep Dec Year
’26 289 394 — — —
’25 106 179 250 279 815
’24 104 39 64 187 393
’23 36 52 52 149 289
’22 8 7 15 24 54
’21 1 1 1 6 9
’20 2 2 3 1 8
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (9) 328 — — —
’25 (15) (10) 2 84 61
’24 (110) (65) (65) (91) (331)
’23 (158) (169) (135) (43) (506)
’22 (147) (125) (85) (166) (522)
’21 (98) (139) (110) (147) (494)
’20 (74) (62) (76) (98) (310)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (18) 324 — — —
’25 (16) (14) 2 80 51
’24 (111) (64) (66) (91) (332)
’23 (159) (170) (136) (43) (508)
’22 (147) (123) (88) (170) (527)
’21 (116) (131) (123) (153) (523)
’20 (80) (68) (78) (103) (329)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1.2
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Jun ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue 5 2 12 15 8 9 54 289 393 815 1,212 +75.7% 1,374 2,009 2,513 +45.6%
Gross margin, % 100.00 100.00 100.00 100.00 100.00 54.71 76.28 83.36 87.83 86.82 91.26 (13.2) pt
EBT (76) (141) (154) (244) (479) (454) (609) (513) (404) (241) 109 +13.7%
EBT margin, % (1,492.23) (8,128.83) (1,233.25) (1,631.78) (6,028.69) (4,936.26) (1,129.12) (177.77) (102.64) (29.53) 8.98 +1,462.7 pt
Net income (76) (140) (154) (244) (479) (454) (614) (521) (409) (258) 866 +14.6%
Per share, $
Per share, $ Revenue 0.19 0.05 0.30 0.32 0.16 0.17 0.96 5.13 6.80 13.44 18.84 +60.3%
Earnings (2.85) (4.33) (3.74) (5.25) (9.46) (8.28) (10.96) (9.24) (7.07) (4.25) 13.87 +4.5%
Cash flow (2.51) (3.20) (3.99) (4.24) (6.13) (9.02) (9.31) (8.99) (5.72) 1.01 6.28 n/m
Capex (0.03) (0.03) (0.08) (0.12) (0.37) (0.52) (0.09) (0.05) (0.01) (0.16) (0.26) +21.2%
Free cash flow (2.53) (3.23) (4.07) (4.36) (6.50) (9.54) (9.41) (9.03) (5.73) 0.85 6.02 n/m
Book value 7.36 6.29 8.05 14.38 18.93 19.09 4.95 (2.80) (1.98) (3.04) 25.96 n/m
Shares, m 27 34 41 47 51 55 56 56 58 61 62 +9.6%
Valuation, ×
Valuation, × P/E 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 18.30 0.0
P/S 103.77 773.87 205.98 431.91 1,062.89 800.73 125.55 24.87 20.25 15.86 13.47 356.6
P/B 2.71 6.32 7.78 9.67 8.81 7.05 24.40 0.00 0.00 0.00 9.78 6.7
EV/Sales 64.62 646.19 179.72 389.93 973.61 725.97 121.11 25.41 21.07 16.22 13.12 316.4
EV/FCF (4.89) (10.29) (13.44) (28.80) (23.50) (12.78) (12.38) (14.43) (24.99) 257.17 41.05 11.2
Cash, $m
Cash, $m Operating cash flow (67) (107) (164) (197) (310) (494) (522) (506) (331) 61 404 n/m
Capex (1) (1) (3) (6) (19) (29) (5) (3) (1) (10) (17) +32.9%
Free cash flow (67) (109) (167) (203) (329) (523) (527) (508) (332) 51 387 n/m
Balance, $m
Balance, $m Working capital 189 204 300 631 785 835 793 547 166 45 1,076 (14.8%)
Net debt (200) (221) (328) (629) (709) (688) (239) 158 321 289 (421) n/m
Shareholders’ equity 195 212 331 669 958 1,045 277 (158) (114) (184) 1,670 n/m
Returns, %
Returns, % ROA (42.51) (62.41) (49.95) (43.04) (50.99) (37.77) (50.54) (51.04) (37.71) (18.76) 44.34 +23.8 pt
ROIC 0.00 0.00 (4,420.67) (397.86) (94.80) (93.45) (968.11) (84,748.35) (91.04) (91.65) 15.07 (91.6) pt
ROE (46.08) (68.81) (56.66) (48.86) (58.84) (45.30) (92.90) (870.08) 300.75 172.80 118.44 +218.9 pt
People
People Employees 101 137 216 330 482 639 797 879 1,017 1,189 — +31.5%
Revenue/emp, $m 0.05 0.01 0.06 0.05 0.02 0.01 0.07 0.33 0.39 0.69 — +33.6%
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Ascendis Pharma A/S vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
INSM Insmed, Inc. $23.9B — (loss-making) — (loss-making) +268.43% (above 0%: growing) n/m +81.06% (above 0%: growing) 85.09% (17.04%) Compare
BNTX BioNTech SE Sponsored ADR $21.6B — (loss-making) — (loss-making) −16.42% (below 0%: shrinking) n/m −123.82% (below 0%: shrinking) 91.99% 9.70% Compare
ALNY Alnylam Pharmaceuticals, Inc. $21.0B 7.9× 13.5× +16.74% (above 0%: growing) +747.64% (above 0%: growing) −4.76% (below 0%: shrinking) 75.19% 23.72% Compare
EXEL Exelixis, Inc. $16.8B 19.9× 20.2× +10.19% (above 0%: growing) +22.22% (above 0%: growing) −4.83% (below 0%: shrinking) 96.02% 40.75% Compare
ASND Ascendis Pharma A/S $16.6B 18.3× 15.4× +119.88% (above 0%: growing) n/m +2,335.93% (above 0%: growing) 91.85% 64.98%
JAZZ Jazz Pharmaceuticals PLC $14.6B 62.6× 35.9× +10.38% (above 0%: growing) n/m −60.40% (below 0%: shrinking) 91.10% (33.26%) Compare
BBIO BridgeBio Pharma, Inc. $14.5B — (loss-making) — (loss-making) +192.60% (above 0%: growing) n/m +60.46% (above 0%: growing) 94.21% (3.30%) Compare
HALO Halozyme Therapeutics, Inc. $14.0B 29.5× 17.9× +39.15% (above 0%: growing) +45.64% (above 0%: growing) −58.64% (below 0%: shrinking) 83.27% 59.83% Compare
SMMT Summit Therapeutics PLC $11.3B — (loss-making) — (loss-making) −100.00% (below 0%: shrinking) n/m −112.80% (below 0%: shrinking) 0.00% 0.00% Compare
Median of peers $15.7B 24.7× 19.0× +13.56% +45.64% −31.73% 88.10% 4.85%

All 621 Biotechnology stocks →

Ascendis Pharma A/S (ASND) Latest News

6 Nov

Impact 3 · · GlobeNewswire

26 Oct

Impact 4 · · GlobeNewswire

20 Oct

Impact 4 · · Investing.com

16 Oct

Impact 4 · · Stocktwits
Impact 4 · · MT Newswires
Impact 4 · · GlobeNewswire

7 Oct

Impact 3 · · Zacks

6 Oct

Impact 4 · · GlobeNewswire

5 Oct

Impact 3 · · Insider Monkey

20 Sep

Impact 3 · · Insider Monkey

19 Sep

Impact 4 ·

17 Sep

Impact 4 ·

16 Sep

Impact 3 ·

15 Sep

Impact 4 ·

14 Sep

Impact 4 ·
Impact 3 ·

10 Sep

Impact 4 ·

9 Sep

Impact 3 ·

4 Sep

Impact 4 ·
Impact 3 ·
Impact 3 ·

3 Sep

Impact 3 ·

31 Aug

Impact 4 ·
Impact 3 · · Stocktwits
Impact 3 ·

25 Aug

Impact 3 ·

21 Aug

Impact 4 ·

20 Aug

Impact 4 · · The Motley Fool transcript
Impact 4 ·

14 Aug

Impact 4 ·

ASND metrics, ten years each

stockrow.com/ASND · Data as of Jun 30, 2026 · For information only; not investment advice. · © 2026 stockrow.com